<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Case reports of Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) in transplant recipients suggest that the risk is markedly elevated </plain></SENT>
<SENT sid="1" pm="."><plain>Therefore, we investigated the incidence of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> in 203,557 solid organ recipients in the U.S </plain></SENT>
<SENT sid="2" pm="."><plain>Transplant <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> Match Study (1987-2009) and compared it with the general population using standardized incidence ratios </plain></SENT>
<SENT sid="3" pm="."><plain>We also assessed associations with demographic and clinical characteristics, and treatments used to induce therapeutic immunosuppression </plain></SENT>
<SENT sid="4" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> incidence was 10.8 per 100,000 person-years, representing 23-fold (95% confidence interval (CI) 19-28) greater risk than in the general population, and it peaked 3-8 years after the time of transplantation </plain></SENT>
<SENT sid="5" pm="."><plain>In adjusted analyses, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> incidence was higher in recipients transplanted when &lt;18 vs. ≥35 years (incidence rate ratio [IRR] 3.49, 95% CI 2.08-5.68) and in those transplanted with a liver (IRR 2.91, 95% CI 1.68-5.09) or heart (IRR 2.39, 95% CI 1.30-4.31) compared with kidney </plain></SENT>
<SENT sid="6" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> incidence was lower in females than males (IRR 0.45, 95% CI 0.28-0.71), in blacks than whites (IRR 0.33, 95% CI 0.12-0.74), in those with a baseline Epstein-Barr virus (EBV)-seropositive versus EBV-seronegative status (IRR 0.34, 95% CI 0.13-0.93), and in those treated with <z:chebi fb="2" ids="2948">azathioprine</z:chebi> (IRR 0.56, 95% CI 0.34-0.89) or <z:chebi fb="0" ids="50858">corticosteroids</z:chebi> (IRR 0.48, 95% CI 0.29-0.82) </plain></SENT>
<SENT sid="7" pm="."><plain><z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">Tumors</z:e> were EBV-positive in 69% of 32 cases with results </plain></SENT>
<SENT sid="8" pm="."><plain>EBV positivity was 90% in those aged &lt;18 years and 59% in those aged 18+ years </plain></SENT>
<SENT sid="9" pm="."><plain>In conclusion, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> risk is markedly elevated in transplant recipients, and it is associated with certain demographic and clinical features </plain></SENT>
<SENT sid="10" pm="."><plain>EBV was positive in most but not <z:hpo ids='HP_0000001'>all</z:hpo> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cases with results </plain></SENT>
<SENT sid="11" pm="."><plain>Am </plain></SENT>
<SENT sid="12" pm="."><plain>J </plain></SENT>
<SENT sid="13" pm="."><plain>Hematol </plain></SENT>
<SENT sid="14" pm="."><plain>88:245-250, 2013. © 2012 Wiley Periodicals, Inc </plain></SENT>
</text></document>